<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1012492</article-id><article-id pub-id-type="publisher-id">ACM-39534</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201200000_77209611.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  脂蛋白(a)与急性ST段抬高型心肌梗死预后的相关性研究
  Study on the Correlation between Lipoprotein (a) and the Prognosis of Acute ST-Segment Elevation Myocardial Infarction
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>少续</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>于</surname><given-names>波涛</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>悦</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>尹</surname><given-names>作民</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青岛大学附属青岛市中心医院，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff2"><addr-line>青岛大学，山东 青岛</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>12</month><year>2020</year></pub-date><volume>10</volume><issue>12</issue><fpage>3288</fpage><lpage>3295</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：分析脂蛋白(a) [Lp (a)]与急性ST段抬高型心肌梗死(STEMI)预后的相关性，为临床提供相关的STEMI预后的参考指标。方法：选取2018年10月~2020年5月在我院急诊病房住院就诊的STEMI患者460例，血清Lp (a)以四分位法分A组(&lt;4.5 mg/dl，120例)，B组(4.5~12.6 mg/dl，112例)，C组(12.7~28.5 mg/dl，116例)，D组(&gt;28.6 mg/dl，112例)。分析4组患者的Lp (a)水平与患者的一般资料、MACCE的单因素与多因素COX回归关系以及特异性、敏感度的情况。结果：随着血清Lp (a)水平上升，空腹血糖水平、HDL-C水平明显较A组降低(P &lt; 0.05)，年龄、脑卒中病史比例、Apo B水平、LVEF &lt; 40%比例明显大于A组(P &lt; 0.05)；四组患者的性别、BMI、吸烟史、高血压病史、糖尿病病病史、血脂异常、心肌梗死病史、PCI史、肌酐、TG、TC、LDL-C、Apo A的临床指标比较，差异均无统计学意义(P &gt; 0.05)。四组患者在PCI术后2年MACCE发生率分别为9.17%、14.28%、13.79%、25.00%，且情况有统计学意义(P &lt; 0.05)，D组MACCE发生率明显高于A组、B组、C组(P均 &lt; 0.05)，但A组、B组、C组两两比较，无统计学意义(P &gt; 0.05)。对单变量分析将P &lt; 0.15或P值 &gt; 0.15，但临床上认为与因变量关系密切的自变量进行多因素COX分析，LVEF &lt; 40%水平是STEMI患者MACCE发生的保护因素，年龄、Lp (a)、冠脉多支病变和脑中风史是独立危险因素。远期MACCE发生率随Lp (a)水平每增加1 mg/dL而提高0.015倍。根据ROC曲线确定Lp (a)的临界值为28.50 mg/dL，Lp (a)预测行直接PCI的STEMI患者术后2年MACCE发生率的特异性为76.78%，敏感度为42.85%。结论：血清Lp (a)水平是直接PCI术后STEMI患者预后MACCE发生的独立危险因素，且随Lp (a)水平增加，累积远期MACCE发生率明显上升。
    Objective: To analyze the correlation between lipoprotein (a) [Lp (a)] and the prognosis of acute ST-segment elevation myocardial infarction (STEMI), to provide clinical reference indicators for the prognosis of STEMI. Methods: From January 2019 to October 2020, 460 STEMI patients who were admitted to the CCU ward of our hospital were selected. Serum Lp (a) was divided into group A (&lt;4.5 mg/dl, 120 cases) and group B by quartile. (4.5 - 12.6 mg/dl, 112 cases), group C (12.7 - 28.5 mg/dl, 116 cases), group D (&gt;28.6 mg/dl, 112 cases). Analyze the Lp (a) level of the 4 groups of patients and the general data of the patients, the regression relationship between the univariate and multivariate COX of MACCE, and the specificity and sensitivity. Results: With the increase of serum Lp (a) levels, fasting blood glucose levels and HDL-C levels were significantly lower than those of group A (P &lt; 0.05), and the proportion of age, stroke history, Apo B levels, and LVEF &lt; 40% were significantly greater than those of group A (P &lt; 0.05); comparison of clinical indicators of gender, BMI, smoking history, hypertension, diabetes, dyslipidemia, myocardial infarction, PCI, creatinine, TG, TC, LDL-C, and Apo A in the four groups, the difference was not statistically significant (P &gt; 0.05). The incidence of MACCE in the four groups of patients at 2 years after PCI was 9.17%, 14.28%, 13.79%, 25.00%, and the situation was statistically significant (P &lt; 0.05). The incidence of MACCE in group D was significantly higher than that in group A and group B. Groups and C groups (all P &lt; 0.05), but there was no statistically significant comparison between groups A, B and C (P &gt; 0.05). For univariate analysis, P &lt; 0.15 or P value &gt; 0.15, but independent variables that are clinically believed to be closely related to the dependent variable are subjected to multivariate COX analysis. LVEF &lt; 40% is a protective factor for MACCE in STEMI patients. Age, Lp (a) multivessel disease of coronary artery and history of stroke are independent risk factors. The incidence of long-term MACCE increased 0.015 times with every 1 mg/dL increase in Lp (a) level. According to the ROC curve, the cut-off value of Lp (a) was 28.50 mg/dL. The specificity of Lp (a) for predicting the incidence of MACCE in STEMI patients undergoing direct PCI at 2 years after surgery was 76.78% and the sensitivity was 42.85%. Conclusion: Serum Lp (a) level is an independent risk factor for the prognosis of MACCE in STEMI patients after direct PCI. With the increase of Lp (a) level, the cumulative long-term MACCE rate increases significantly. 
  
 
</p></abstract><kwd-group><kwd>急性ST段抬高型心肌梗死，脂蛋白(a)，特异性，敏感度, Acute ST-Segment Elevation Myocardial Infarction</kwd><kwd> Lipoprotein (a)</kwd><kwd> Specificity</kwd><kwd> Sensitivity</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：分析脂蛋白(a) [Lp (a)]与急性ST段抬高型心肌梗死(STEMI)预后的相关性，为临床提供相关的STEMI预后的参考指标。方法：选取2018年10月~2020年5月在我院急诊病房住院就诊的STEMI患者460例，血清Lp (a)以四分位法分A组(&lt;4.5 mg/dl，120例)，B组(4.5~12.6 mg/dl，112例)，C组(12.7~28.5 mg/dl，116例)，D组(&gt;28.6 mg/dl，112例)。分析4组患者的Lp (a)水平与患者的一般资料、MACCE的单因素与多因素COX回归关系以及特异性、敏感度的情况。结果：随着血清Lp (a)水平上升，空腹血糖水平、HDL-C水平明显较A组降低(P &lt; 0.05)，年龄、脑卒中病史比例、Apo B水平、LVEF &lt; 40%比例明显大于A组(P &lt; 0.05)；四组患者的性别、BMI、吸烟史、高血压病史、糖尿病病病史、血脂异常、心肌梗死病史、PCI史、肌酐、TG、TC、LDL-C、Apo A的临床指标比较，差异均无统计学意义(P &gt; 0.05)。四组患者在PCI术后2年MACCE发生率分别为9.17%、14.28%、13.79%、25.00%，且情况有统计学意义(P &lt; 0.05)，D组MACCE发生率明显高于A组、B组、C组(P均 &lt; 0.05)，但A组、B组、C组两两比较，无统计学意义(P &gt; 0.05)。对单变量分析将P &lt; 0.15或P值 &gt; 0.15，但临床上认为与因变量关系密切的自变量进行多因素COX分析，LVEF &lt; 40%水平是STEMI患者MACCE发生的保护因素，年龄、Lp (a)、冠脉多支病变和脑中风史是独立危险因素。远期MACCE发生率随Lp (a)水平每增加1 mg/dL而提高0.015倍。根据ROC曲线确定Lp (a)的临界值为28.50 mg/dL，Lp (a)预测行直接PCI的STEMI患者术后2年MACCE发生率的特异性为76.78%，敏感度为42.85%。结论：血清Lp (a)水平是直接PCI术后STEMI患者预后MACCE发生的独立危险因素，且随Lp (a)水平增加，累积远期MACCE发生率明显上升。</p></sec><sec id="s2"><title>关键词</title><p>急性ST段抬高型心肌梗死，脂蛋白(a)，特异性，敏感度</p></sec><sec id="s3"><title>Study on the Correlation between Lipoprotein (a) and the Prognosis of Acute ST-Segment Elevation Myocardial Infarction</title><p>Shaoxu Zhang<sup>1</sup>, Botao Yu<sup>2</sup>, Yue Wang<sup>2</sup>, Zuomin Yin<sup>2*</sup></p><p><sup>1</sup>Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Affiliated Qingdao Central Hospital, Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/62-1571782x5_hanspub.png" /></p><p>Received: Nov. 27<sup>th</sup>, 2020; accepted: Dec. 23<sup>rd</sup>, 2020; published: Dec. 30<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/62-1571782x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To analyze the correlation between lipoprotein (a) [Lp (a)] and the prognosis of acute ST-segment elevation myocardial infarction (STEMI), to provide clinical reference indicators for the prognosis of STEMI. Methods: From January 2019 to October 2020, 460 STEMI patients who were admitted to the CCU ward of our hospital were selected. Serum Lp (a) was divided into group A (&lt;4.5 mg/dl, 120 cases) and group B by quartile. (4.5 - 12.6 mg/dl, 112 cases), group C (12.7 - 28.5 mg/dl, 116 cases), group D (&gt;28.6 mg/dl, 112 cases). Analyze the Lp (a) level of the 4 groups of patients and the general data of the patients, the regression relationship between the univariate and multivariate COX of MACCE, and the specificity and sensitivity. Results: With the increase of serum Lp (a) levels, fasting blood glucose levels and HDL-C levels were significantly lower than those of group A (P &lt; 0.05), and the proportion of age, stroke history, Apo B levels, and LVEF &lt; 40% were significantly greater than those of group A (P &lt; 0.05); comparison of clinical indicators of gender, BMI, smoking history, hypertension, diabetes, dyslipidemia, myocardial infarction, PCI, creatinine, TG, TC, LDL-C, and Apo A in the four groups, the difference was not statistically significant (P &gt; 0.05). The incidence of MACCE in the four groups of patients at 2 years after PCI was 9.17%, 14.28%, 13.79%, 25.00%, and the situation was statistically significant (P &lt; 0.05). The incidence of MACCE in group D was significantly higher than that in group A and group B. Groups and C groups (all P &lt; 0.05), but there was no statistically significant comparison between groups A, B and C (P &gt; 0.05). For univariate analysis, P &lt; 0.15 or P value &gt; 0.15, but independent variables that are clinically believed to be closely related to the dependent variable are subjected to multivariate COX analysis. LVEF &lt; 40% is a protective factor for MACCE in STEMI patients. Age, Lp (a) multivessel disease of coronary artery and history of stroke are independent risk factors. The incidence of long-term MACCE increased 0.015 times with every 1 mg/dL increase in Lp (a) level. According to the ROC curve, the cut-off value of Lp (a) was 28.50 mg/dL. The specificity of Lp (a) for predicting the incidence of MACCE in STEMI patients undergoing direct PCI at 2 years after surgery was 76.78% and the sensitivity was 42.85%. Conclusion: Serum Lp (a) level is an independent risk factor for the prognosis of MACCE in STEMI patients after direct PCI. With the increase of Lp (a) level, the cumulative long-term MACCE rate increases significantly.</p><p>Keywords:Acute ST-Segment Elevation Myocardial Infarction, Lipoprotein (a), Specificity, Sensitivity</p><disp-formula id="hanspub.39534-formula77"><graphic xlink:href="//html.hanspub.org/file/62-1571782x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/62-1571782x8_hanspub.png" /> <img src="//html.hanspub.org/file/62-1571782x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>低密度脂蛋白胆固醇(LDL-C)增高作为以往研究动脉粥样硬化重要的危险因素而最受关注，但是仍存在部分冠心病患者(LDL-C &lt; 1.8 mmol/L)病情不断进展的残余风险 [<xref ref-type="bibr" rid="hanspub.39534-ref1">1</xref>]，而近年来发现由附着载脂蛋白的低密度脂蛋白样颗粒与载脂蛋白-a构成的一种特殊的脂蛋白(a) [Lp (a)]对心血管疾病预后影响存在较高的相关性，是独立危险因素 [<xref ref-type="bibr" rid="hanspub.39534-ref2">2</xref>]。已证实的缺血性心脏病中，Lp (a)与新的心血管事件之间的关系显示出矛盾的结果 [<xref ref-type="bibr" rid="hanspub.39534-ref3">3</xref>]。目前针对急性ST段抬高型心肌梗死(STEMI)的特殊人群的研究报道相对较少，尤其患者Lp (a)阈值水平与远期不良心脑血管事件发生情况关系。本研究拟探究Lp (a)阈值水平对STEMI患者预后影响，为临床决策提供参考与理论依据。现报道如下：</p></sec><sec id="s6"><title>2. 材料与方法</title><sec id="s6_1"><title>2.1. 入选对象</title><p>选取2018年10月~2020年5月在我院急诊病房住院就诊的STEMI患者460例。纳入标准：① 符合STEMI诊断和治疗指南(2019) [<xref ref-type="bibr" rid="hanspub.39534-ref4">4</xref>]；② 急诊冠脉造影及直接经皮冠状动脉支架植入术(PCI)者，发生时间在48 h以内；③ 血清标志物水平的动态改变，血清肌酸磷化脢–同功脢(CK-MB) ≥ 正常值上限2倍以上；④ 胸痛持续时间 &gt; 30 min，入院至诊疗时间 &lt; 12 h，或 &gt; 12 h仍存在心肌缺血证据者；⑤ 心电图呈动态演变者，ST段在至少2个肢导联抬高 ≥ 0.1 mV，或相连的至少2个胸导联抬高 ≥ 0.2 mV [<xref ref-type="bibr" rid="hanspub.39534-ref5">5</xref>]；⑥ 患者签署知情同意书。排除标准：① 肾功能不全或尿毒症者；② 肝肾功能异常，合并脑、肺、肝、肾、脾或四肢等动脉栓塞者；③ 单纯行冠状动脉造影者；④ 恶性肿瘤、免疫系统疾病者；⑤ 弥散性血管内凝血、甲状腺功能异常者；⑥ 合并急慢性感染、血液系统疾病者；⑦ 住院前1个月内曾服用过他汀类、烟酸类等影响本次研究的药物者；⑧ 失访及资料不完整者。入选患者根据血清Lp (a)以四分位法分A组(&lt;4.5 mg/dl，60例)，B组(4.5~12.6 mg/dl，56例)，C组(12.7~28.5 mg/dl，58例)，D组(&gt;28.6 mg/dl，56例)。分析4组患者的Lp (a)水平与患者的一般资料、MACCE的单因素与多因素COX回归关系以及特异性、敏感度的情况。</p></sec><sec id="s6_2"><title>2.2. 方法</title><sec id="s6_2_1"><title>2.2.1. 常规的PCI与治疗方法</title><p>按常规方法植入支架，计划直接PCI的STEMI患者，术前尽早给予阿司匹林300 mg负荷量，同时给予氯吡格雷300~600 mg或替格瑞洛180 mg负荷量。术中经动脉鞘管给予肝素100 U/kg，如果手术时间超过l h再追加普通肝素1000 U。根据临床和病变情况由术者决定是否应用血小板膜糖蛋白IIb/IIIa受体拮抗剂。术后给予阿司匹林100 mg (每日1次口服)和氯吡格雷75 mg (每日1次口服)或替格瑞洛90 mg (每日2次口服)的双联抗血小板治疗至少1年。</p></sec><sec id="s6_2_2"><title>2.2.2. 记录临床相关的资料</title><p>包括年龄、性别、体质指数(BMI)、吸烟史(每天至少一支连续一年以上，或者长期吸烟但戒烟短于半年的为阳性)；既往病史：既往心力衰竭病史、高血压病史(收缩压 ≥ 140 mmHg和/或舒张压 ≥ 90 mmHg)、心肌梗死病史、糖尿病病史：至少符合以下任意一条标准，即明确T2DM病史，胰岛素治疗或口服降血糖药物，空腹血糖 ≥ 7 mmol/L，糖化血红蛋白(HbA1c ≥ 6.5%)、脑卒中病史(局灶性神经功能缺持续24 h以上乃至死亡)、PCI史；化验检查指标：包括空腹血糖、血肌酐、血脂。而血脂异常：至少符合以下任意一条标准，即总胆固醇(TC) &gt; 5.18 mmol/L、甘油三脂(TG) &gt; 1.7 mmol/L、低密度脂蛋白胆固醇(LDL-C) &gt; 3.37 mmol/L、高密度脂蛋白胆固醇(HDL-C) &lt; 1.04 mmol/L、载脂蛋白A (Apo A &lt; 0.97 g/L)、载脂蛋白B (Apo A &gt; 1.0 g/L)、左室射血分数(LVEF) &lt; 40%、冠状动脉病变史(至少2支或左主干病变) [<xref ref-type="bibr" rid="hanspub.39534-ref6">6</xref>]。</p></sec><sec id="s6_2_3"><title>2.2.3. 不良心脑血管事件随访</title><p>出院后进行随访两年，记录非致死性心肌梗死、心源性死亡、无计划血运重建、脑卒中发生的主要不良心脑血管事件(MACCE)。</p></sec></sec><sec id="s6_3"><title>2.3. 统计学分析</title><p>选择SPSS18.0统计软件进行数据分析，计数资料以n(%)表示，χ<sup>2</sup>检验，计量资料以( x &#175; &#177; s )表示，行t检验，将Lp (a)作为连续变量，行多因素COX回归分析；以约登指数确定最佳临界点构建受试者工作特征(ROC)曲线分析，以P &lt; 0.05有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 四组的临床资料比较</title><p>四组患者的性别、BMI、吸烟史、高血压病史、糖尿病病史、血脂异常、心肌梗死病史、PCI史、肌酐、TG、TC、LDL-C、Apo A的临床指标比较，差异均无统计学意义(P &gt; 0.05)。随着血清Lp (a)水平上升，空腹血糖水平、HDL-C水平明显较A组降低(P &lt; 0.05)，且Lp (a)水平越高对应的空腹血糖水平与HDL-C水平越低，年龄、脑卒中病史比例、Apo A水平、LVEF &lt; 40%比例明显大于A组(P &lt; 0.05)。见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of clinical data in four groups ( x &#175; &#177; s , n (%)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >项目</th><th align="center" valign="middle" >A组(n = 120)</th><th align="center" valign="middle" >B组(n = 112)</th><th align="center" valign="middle" >C组(n = 116)</th><th align="center" valign="middle" >D组(n = 112)</th><th align="center" valign="middle" >F/χ<sup>2</sup>值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" >59.03 &#177; 6.32</td><td align="center" valign="middle" >60.62 &#177; 5.41<sup>*</sup></td><td align="center" valign="middle" >61.35 &#177; 5.89<sup>*#</sup></td><td align="center" valign="middle" >62.11 &#177; 6.52<sup>*#&amp;</sup></td><td align="center" valign="middle" >5.512</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >性别–男性[n (%)]</td><td align="center" valign="middle" >90 (75.00)</td><td align="center" valign="middle" >86 (76.78)</td><td align="center" valign="middle" >90 (77.58)</td><td align="center" valign="middle" >90 (80.35)</td><td align="center" valign="middle" >1.826</td><td align="center" valign="middle" >0.609</td></tr><tr><td align="center" valign="middle" >BMI (kg/m<sup>2</sup>)</td><td align="center" valign="middle" >25.16 &#177; 1.42</td><td align="center" valign="middle" >24.83 &#177; 1.55</td><td align="center" valign="middle" >25.24 &#177; 1.63</td><td align="center" valign="middle" >25.27 &#177; 1.74</td><td align="center" valign="middle" >1.823</td><td align="center" valign="middle" >0.142</td></tr><tr><td align="center" valign="middle" >吸烟史[n (%)]</td><td align="center" valign="middle" >63 (52.50)</td><td align="center" valign="middle" >60 (53.57)</td><td align="center" valign="middle" >60 (51.72)</td><td align="center" valign="middle" >62 (55.35)</td><td align="center" valign="middle" >0.340</td><td align="center" valign="middle" >0.952</td></tr><tr><td align="center" valign="middle" >高血压病史[n (%)]</td><td align="center" valign="middle" >58 (48.33)</td><td align="center" valign="middle" >57 (50.89)</td><td align="center" valign="middle" >60 (51.72)</td><td align="center" valign="middle" >54 (48.21)</td><td align="center" valign="middle" >0.441</td><td align="center" valign="middle" >0.931</td></tr><tr><td align="center" valign="middle" >糖尿病病史[n (%)]</td><td align="center" valign="middle" >32 (26.67)</td><td align="center" valign="middle" >31 (27.67)</td><td align="center" valign="middle" >32 (27.59)</td><td align="center" valign="middle" >33 (29.46)</td><td align="center" valign="middle" >0.234</td><td align="center" valign="middle" >0.971</td></tr><tr><td align="center" valign="middle" >心肌梗死病史[n (%)]</td><td align="center" valign="middle" >10 (8.33)</td><td align="center" valign="middle" >8 (7.14)</td><td align="center" valign="middle" >8 (6.89)</td><td align="center" valign="middle" >10 (8.93)</td><td align="center" valign="middle" >0.442</td><td align="center" valign="middle" >0.931</td></tr><tr><td align="center" valign="middle" >血脂异常[n (%)]</td><td align="center" valign="middle" >85 (70.83)</td><td align="center" valign="middle" >86 (76.78)</td><td align="center" valign="middle" >84 (72.41)</td><td align="center" valign="middle" >85 (75.89)</td><td align="center" valign="middle" >1.432</td><td align="center" valign="middle" >0.697</td></tr><tr><td align="center" valign="middle" >脑卒中病史[n (%)]</td><td align="center" valign="middle" >6 (5.00)</td><td align="center" valign="middle" >15 (13.39)<sup>*</sup></td><td align="center" valign="middle" >17 (14.65)<sup>*</sup></td><td align="center" valign="middle" >20 (17.85)<sup>*</sup></td><td align="center" valign="middle" >9.608</td><td align="center" valign="middle" >0.022</td></tr><tr><td align="center" valign="middle" >PCI史[n (%)]</td><td align="center" valign="middle" >6 (10.00)</td><td align="center" valign="middle" >6 (10.71)</td><td align="center" valign="middle" >7 (12.07)</td><td align="center" valign="middle" >7 (14.28)</td><td align="center" valign="middle" >0.220</td><td align="center" valign="middle" >0.974</td></tr><tr><td align="center" valign="middle" >肌酐(μmol/L)</td><td align="center" valign="middle" >69.81 &#177; 9.22</td><td align="center" valign="middle" >72.03 &#177; 9.73</td><td align="center" valign="middle" >71.84 &#177; 9.65</td><td align="center" valign="middle" >73.14 &#177; 9.24</td><td align="center" valign="middle" >2.393</td><td align="center" valign="middle" >0.067</td></tr><tr><td align="center" valign="middle" >空腹血糖(mmol/L)</td><td align="center" valign="middle" >6.62 &#177; 0.68</td><td align="center" valign="middle" >6.36 &#177; 0.55<sup>*</sup></td><td align="center" valign="middle" >6.12 &#177; 0.48<sup>*#</sup></td><td align="center" valign="middle" >5.96 &#177; 0.45<sup>*#&amp;</sup></td><td align="center" valign="middle" >32.02</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >TC (mmol/L)</td><td align="center" valign="middle" >4.87 &#177; 1.02</td><td align="center" valign="middle" >4.76 &#177; 1.06</td><td align="center" valign="middle" >4.82 &#177; 1.11</td><td align="center" valign="middle" >4.91 &#177; 1.05</td><td align="center" valign="middle" >0.072</td><td align="center" valign="middle" >0.977</td></tr><tr><td align="center" valign="middle" >TG (mmol/L)</td><td align="center" valign="middle" >1.62 &#177; 0.57</td><td align="center" valign="middle" >1.56 &#177; 0.62</td><td align="center" valign="middle" >1.53 &#177; 0.78</td><td align="center" valign="middle" >1.46 &#177; 0.71</td><td align="center" valign="middle" >1.133</td><td align="center" valign="middle" >0.338</td></tr><tr><td align="center" valign="middle" >LDL-C (mmol/L)</td><td align="center" valign="middle" >3.11 &#177; 0.79</td><td align="center" valign="middle" >2.96 &#177; 0.74</td><td align="center" valign="middle" >2.89 &#177; 0.70</td><td align="center" valign="middle" >2.93 &#177; 0.81</td><td align="center" valign="middle" >1.891</td><td align="center" valign="middle" >0.131</td></tr><tr><td align="center" valign="middle" >HDL-C (mmol/L)</td><td align="center" valign="middle" >1.32 &#177; 0.42</td><td align="center" valign="middle" >1.15 &#177; 0.27<sup>*</sup></td><td align="center" valign="middle" >1.08 &#177; 0.25<sup>*#</sup></td><td align="center" valign="middle" >1.02 &#177; 0.22<sup>*#&amp;</sup></td><td align="center" valign="middle" >21.602</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >Apo B (mmol/L)</td><td align="center" valign="middle" >1.13 &#177; 0.35</td><td align="center" valign="middle" >1.08 &#177; 0.32</td><td align="center" valign="middle" >1.12 &#177; 0.35</td><td align="center" valign="middle" >1.17 &#177; 0.33</td><td align="center" valign="middle" >1.343</td><td align="center" valign="middle" >0.260</td></tr><tr><td align="center" valign="middle" >Apo A (mmol/L)</td><td align="center" valign="middle" >0.91 &#177; 0.17</td><td align="center" valign="middle" >0.96 &#177; 0.21</td><td align="center" valign="middle" >0.98 &#177; 0.27</td><td align="center" valign="middle" >1.03 &#177; 0.26<sup>*</sup></td><td align="center" valign="middle" >5.384</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >LVEF &lt; 40% [n (%)]</td><td align="center" valign="middle" >4 (3.33)</td><td align="center" valign="middle" >8 (7.14)</td><td align="center" valign="middle" >14 (12.07)<sup>*</sup></td><td align="center" valign="middle" >14 (14.28)<sup>*</sup></td><td align="center" valign="middle" >8.390</td><td align="center" valign="middle" >0.038</td></tr><tr><td align="center" valign="middle" >冠状动脉病变史[n (%)]</td><td align="center" valign="middle" >50 (41.67)</td><td align="center" valign="middle" >50 (44.64)</td><td align="center" valign="middle" >54 (46.55)</td><td align="center" valign="middle" >52 (46.42)</td><td align="center" valign="middle" >1.115</td><td align="center" valign="middle" >0.773</td></tr></tbody></table></table-wrap><p>表1. 四组的临床资料比较( x &#175; &#177; s , n (%))</p><p>注：与A组比较，<sup>*</sup>P &lt; 0.01；与B组比较，<sup>#</sup>P &lt; 0.01；与C组比较，<sup>&amp;</sup>P &lt; 0.01。</p></sec><sec id="s7_2"><title>3.2. 四组PCI术后2年MACCE的临床单因素分析</title><p>四组患者在PCI术后2年MACCE发生率分别为9.17%、14.28%、13.79%、25.00%，且情况有统计学意义(P &lt; 0.05)，D组MACCE发生率明显高于A组、B组、C组(P均 &lt; 0.05)，但A组、B组、C组两两比较，无统计学意义(P &gt; 0.05)。见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Clinical single factor analysis of MACCE for 2 years after four groups of PCI [n (%)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >MACCE</th><th align="center" valign="middle" >A组(n = 120)</th><th align="center" valign="middle" >B组(n = 112)</th><th align="center" valign="middle" >C组(n = 116)</th><th align="center" valign="middle" >D组(n = 112)</th><th align="center" valign="middle" >χ<sup>2</sup>值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >脑卒中</td><td align="center" valign="middle" >0 (0.00)</td><td align="center" valign="middle" >0 (0.00)</td><td align="center" valign="middle" >0 (0.00)</td><td align="center" valign="middle" >4 (3.57)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >心源性死亡</td><td align="center" valign="middle" >6 (5.00)</td><td align="center" valign="middle" >5 (4.46)</td><td align="center" valign="middle" >6 (5.17)</td><td align="center" valign="middle" >11 (9.82)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >非致死性心肌梗死</td><td align="center" valign="middle" >2 (1.67)</td><td align="center" valign="middle" >6 (5.36)</td><td align="center" valign="middle" >4 (3.45)</td><td align="center" valign="middle" >6 (4.46)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >无计划的血运重建</td><td align="center" valign="middle" >3 (2.50)</td><td align="center" valign="middle" >5 (4.46)</td><td align="center" valign="middle" >6 (5.17)</td><td align="center" valign="middle" >7 (6.25)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >合计</td><td align="center" valign="middle" >11 (9.17)</td><td align="center" valign="middle" >16 (14.28)</td><td align="center" valign="middle" >16 (13.79)</td><td align="center" valign="middle" >28 (25.00)<sup>*#&amp;</sup></td><td align="center" valign="middle" >11.815</td><td align="center" valign="middle" >0.008</td></tr></tbody></table></table-wrap><p>表2. 四组PCI术后2年MACCE的临床单因素分析[n (%)]</p><p>注：与A组比较，<sup>*</sup>P &lt; 0.01；与B组比较，<sup>#</sup>P &lt; 0.01；与C组比较，<sup>&amp;</sup>P &lt; 0.01。</p></sec><sec id="s7_3"><title>3.3. PCI术后2年MACCE发生的多元COX回归分析</title><p>对单变量分析将P &lt; 0.15或P值 &gt; 0.15，但临床上认为与因变量关系密切的自变量进行多因素COX分析，LVEF &lt; 40%水平是STEMI患者MACCE发生的保护因素，年龄、Lp (a)、冠脉多支病变和脑中风史是独立危险因素。远期MACCE发生率随Lp (a)水平每增加l mg/dL而提高0.015倍。见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Multivariate COX regression analysis of MACCE occurring in 2 years after PCI surgery ( x &#175; &#177; s , %</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >MACCE</th><th align="center" valign="middle" >B</th><th align="center" valign="middle" >HR</th><th align="center" valign="middle" >95% CI</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" >0.114</td><td align="center" valign="middle" >1.121</td><td align="center" valign="middle" >1.004~1.056</td><td align="center" valign="middle" >0.014</td></tr><tr><td align="center" valign="middle" >Lp (a)</td><td align="center" valign="middle" >0.015</td><td align="center" valign="middle" >1.015</td><td align="center" valign="middle" >1.005~1.033</td><td align="center" valign="middle" >0.003</td></tr><tr><td align="center" valign="middle" >冠脉多支病变</td><td align="center" valign="middle" >0.700</td><td align="center" valign="middle" >2.014</td><td align="center" valign="middle" >1.124~3.475</td><td align="center" valign="middle" >0.017</td></tr><tr><td align="center" valign="middle" >LVEF &lt; 40%</td><td align="center" valign="middle" >−0.066</td><td align="center" valign="middle" >0.936</td><td align="center" valign="middle" >0.921~0.978</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >脑卒中病史</td><td align="center" valign="middle" >0.757</td><td align="center" valign="middle" >2.132</td><td align="center" valign="middle" >1.043~4.573</td><td align="center" valign="middle" >0.038</td></tr></tbody></table></table-wrap><p>表3. PCI术后2年MACCE发生的多元COX回归分析( x &#175; &#177; s , %)</p></sec><sec id="s7_4"><title>3.4. 术后2年Lp (a)预测MACCE发生率的临床特异性与灵敏度分析</title><p>考虑Lp (a)水平的某一阈值与远期MACCE发生率的相关性，通过构建ROC曲线来判定Lp (a)的最佳截止值，结果显示Lp (a)的临界值为28.50 mg/dL时，Lp (a)预测行直接PCI的STEMI患者术后2年MACCE发生率的特异性为76.78%，敏感度为42.85%。见图1。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>STEMI是冠状动脉疾病的最危急表现，并与高发病率和高死亡率相关。在大多数情况下，心外膜冠状动脉粥样硬化斑块破裂后继发冠状动脉血栓性阻塞是STEMI的原因。早期诊断和立即再灌注可以限制心肌缺血和梗塞面积，是降低STEMI后并发症和心力衰竭风险的最有效方法 [<xref ref-type="bibr" rid="hanspub.39534-ref7">7</xref>]。原发性经皮冠状动脉介入治疗(PCI)已成为STEMI患者的首选再灌注策略。如果在STEMI诊断后120分钟内不能进行PCI，则</p><p>图1. 术后2年Lp (a)预测MACCE发生率的临床特异性与灵敏度分析</p><p>应进行纤溶治疗以溶解闭塞性血栓。提供全天候心脏导管插入功能的网络的启动以及医院系统内标准操作程序的产生，有助于减少再灌注治疗的时间 [<xref ref-type="bibr" rid="hanspub.39534-ref8">8</xref>]，加上抗血栓治疗和预防措施的新进展，这些进展已导致STEMI死亡率降低。但是，仍有大量患者在STEMI后仍然经历心血管疾病的复发。关于STEMI的病理生理学获得了新的见识，并为新的治疗策略的发展提供了帮助。</p><p>尽管在预防，诊断和治疗方面取得了进步，但冠状动脉疾病(CAD)仍然是全球范围内的主要死亡原因。本研究显示，STEMI患者的性别、BMI、吸烟史、高血压病史、糖尿病病病史、血脂异常、心肌梗死病史、PCI史、肌酐、TG、TC、LDL-C、Apo B的临床指标不是增加MACCE发生风险的危险因素。多种方法，包括不同途径的生物标记物和风险量表，已试图鉴定出具有缺血性心脏病病史的患者，这些患者遭受新的缺血性事件的风险更大 [<xref ref-type="bibr" rid="hanspub.39534-ref9">9</xref>]。在这种情况下，传统的危险因素不足以对这些患者的危险进行分类，而其他生物标记物无法在实验水平之外建立自己的地位 [<xref ref-type="bibr" rid="hanspub.39534-ref10">10</xref>]。Lp (a)是由肝脏合成的低密度脂蛋白(LDL)样颗粒，由通过二硫键与糖蛋白载脂蛋白a共价连接的载脂蛋白B100分子组成。尽管Lp (a)对脉管系统的直接作用尚不完全清楚，但有人提出了Lp (a)在血管内膜中的作用，血栓形成和泡沫细胞形成，所有这些都与动脉粥样硬化和血栓形成有关 [<xref ref-type="bibr" rid="hanspub.39534-ref11">11</xref>]。本研究结果显示，随着血清Lp (a)水平上升，空腹血糖水平、HDL-C水平明显较A组降低(P &lt; 0.05)，年龄、脑卒中病史比例、Apo A水平、LVEF &lt; 40%比例明显大于A组。尽管人们认为Lp (a)对动脉粥样硬化具有与LDL胆固醇相似的作用，但由于其Apo A成分，据报道其具有更大的致动脉粥样硬化作用 [<xref ref-type="bibr" rid="hanspub.39534-ref12">12</xref>]。另外，还已经通过不同的机制提出了增强的蛋白原的促发，促动脉粥样硬化和血栓形成作用，Lp (a)可能通过增加氧化磷脂的结合，增强单核细胞的迁移和细胞因子的产生以及上调基因的表达而促进氨基化 [<xref ref-type="bibr" rid="hanspub.39534-ref13">13</xref>]。Apo A颗粒中包含的赖氨酸结合位点的存在允许Lp (a)积累到内膜下空间，从而促进氨基化，泡沫细胞形成，平滑肌细胞增殖，基质结合的上调，从而使动脉粥样硬化 [<xref ref-type="bibr" rid="hanspub.39534-ref14">14</xref>]。事实上，Apo A的存在直接与不稳定的斑块和血栓形成的风险增加直接相关，这主要是通过抑制血纤蛋白降解过程和上调血小板反应性来实现的 [<xref ref-type="bibr" rid="hanspub.39534-ref15">15</xref>]。</p><p>长期以来，Lp (a)被认为是一般人群中心血管疾病的潜在危险因素，尤其是在极高的值时 [<xref ref-type="bibr" rid="hanspub.39534-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.39534-ref17">17</xref>]。此外，它的测量结果显示了改善心血管风险预测的效用，特别是在那些处于中等风险的人群中 [<xref ref-type="bibr" rid="hanspub.39534-ref18">18</xref>]。但是，尚未明确评估Lp (a)增加与冠心病患者进一步冠状动脉事件风险之间的关系，特别是在很长的随访中。本研究结果显，STEMI患者在PCI术后2年MACCE发生率分别为9.17%、14.28%、13.79%、25.00%，且D组MACCE发生率明显高于A组、B组、C组。对单变量分析将P &lt; 0.15或P值 &gt; 0.15，但临床上认为与因变量关系密切的自变量进行多因素COX分析，LVEF &lt; 40%水平是STEMI患者MACCE发生的保护因素，年龄、Lp (a)、冠脉多支病变和脑中风史是独立危险因素。远期MACCE发生率随Lp (a)水平每增加l mg/dL而提高0.015倍。根据ROC曲线确定Lp (a)的临界值为28.50 mg/dL，Lp (a)预测行直接PCI的STEMI患者术后2年MACCE发生率的特异性为76.78%，敏感度为42.85%。Lp (a)是由基因决定的，据报道是动脉粥样硬化性血管疾病的独立危险因素 [<xref ref-type="bibr" rid="hanspub.39534-ref19">19</xref>]。但是，Lp (a)对冠状动脉疾病后患者继发性血管事件的预后价值尚未完全阐明，Lp (a)的生理作用尚不清楚，但是这些问题有待进一步的研究 [<xref ref-type="bibr" rid="hanspub.39534-ref20">20</xref>]。</p><p>综上所述，血清Lp (a)水平是直接PCI术后STEMI患者预后MACCE发生的独立危险因素，且随Lp (a)水平增加，累积远期MACCE发生率明显上升。</p></sec><sec id="s9"><title>文章引用</title><p>张少续,于波涛,王 悦,尹作民. 脂蛋白(a)与急性ST段抬高型心肌梗死预后的相关性研究Study on the Correlation between Lipoprotein (a) and the Prognosis of Acute ST-Segment Elevation Myocardial Infarction[J]. 临床医学进展, 2020, 10(12): 3288-3295. https://doi.org/10.12677/ACM.2020.1012492</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39534-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">王慧, 尹良平, 程丽, 等. 单核细胞/高密度脂蛋白胆固醇比值与急性ST段抬高型心肌梗死患者短期预后的相关性研究[J]. 中国循证心血管医学杂志, 2018, 10(3): 331-333.</mixed-citation></ref><ref id="hanspub.39534-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Miñana, G., Gil-Cayuela, C., Bodi, V., et al. (2020) Lipoprotein(a) and Long-Term Recurrent Infarction after an Episode of ST-Segment Elevation Acute Myocardial Infarction. Coronary Artery Disease, 31, 378-384.  
&lt;br&gt;https://doi.org/10.1097/MCA.0000000000000852</mixed-citation></ref><ref id="hanspub.39534-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">叶子, 李勇. 脂蛋白(a)与心血管病临床研究的现状及展望[J]. 中华心血管病杂志, 2019, 47(12): 1013-1017.</mixed-citation></ref><ref id="hanspub.39534-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南(2019) [J]. 中华心血管病杂志, 2019, 47(10): 766-783.</mixed-citation></ref><ref id="hanspub.39534-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Gao, M., Zhao, W., Zhang, Z., et al. (2018) Clinical Characteristics and Outcomes in Young Patients with ST-Segment Elevation Myocardial Infarction after Primary Percutaneous Coronary Intervention. The American Journal of the Medical Sciences, 355, 544-552. &lt;br&gt;https://doi.org/10.1016/j.amjms.2018.02.003</mixed-citation></ref><ref id="hanspub.39534-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">郭远林, 陈纪林. 2019年欧洲血脂异常管理指南对我国临床实践的启示[J]. 中国循环杂志, 2020, 35(2): 105-107.</mixed-citation></ref><ref id="hanspub.39534-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">谷阳, 于昆, 徐琢, 等. 脂蛋白(a)对非ST段抬高型急性冠状动脉综合征患者风险评估的价值[J]. 中华老年心脑血管病杂志, 2018, 20(2): 149-152.</mixed-citation></ref><ref id="hanspub.39534-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">刘雅婷, 谷新顺, 张芳, 等. 前壁急性ST段抬高型心肌梗死患者直接经皮冠状动脉介入术后主要不良心血管事件发生的影响因素[J]. 中华实用诊断与治疗杂志, 2020, 34(5): 79-82.</mixed-citation></ref><ref id="hanspub.39534-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Gao, M., Qin, L., Zhang, Z., et al. (2019) Treatment Windows and Clinical Outcomes in Late-Presenting Patients with ST-Segment Elevation Myocardial Infarction. The American Journal of the Medical Sciences, 358, 248-255.  
&lt;br&gt;https://doi.org/10.1016/j.amjms.2019.04.026</mixed-citation></ref><ref id="hanspub.39534-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">孙西锋, 倪广臻, 潘祥坡, 等. 脂蛋白(a)对急性ST段抬高型心肌梗死患者行经皮冠状动脉介入术后发生对比剂肾病的影响[J]. 中华高血压杂志, 2019, 27(3): 262-266.</mixed-citation></ref><ref id="hanspub.39534-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Haig, C., Carrick, D., Carberry, J., et al. (2019) Current Smoking and Prognosis after Acute ST-Segment Elevation Myocardial Infarction: New Pathophysiological Insights. JACC: Cardiovascular Imaging, 12, 993-1003.  
&lt;br&gt;https://doi.org/10.1016/j.jcmg.2018.05.022</mixed-citation></ref><ref id="hanspub.39534-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">王苗苗. 急性ST段抬高型心肌梗死合并心律失常病人短期预后的影响因素研究[J]. 中西医结合心脑血管病杂志, 2018, 16(9): 1241-1244.</mixed-citation></ref><ref id="hanspub.39534-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">丁慧, 李朱萌, 王寅, 等. 急性冠状动脉综合征患者血清脂蛋白(a)及同型半胱氨酸水平分析[J]. 检验医学, 2019, 34(12): 1082-1087.</mixed-citation></ref><ref id="hanspub.39534-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Bessonov, I.S., Kuznetsov, V.A., Dyakova, A.O., et al. (2020) Percutaneous Coronary Interventions in Patients with ST-Elevation Myocardial Infarction: 10-Years Follow-Up. Kardiologiia, 60, 982-988.  
&lt;br&gt;https://doi.org/10.18087/cardio.2020.6.n982</mixed-citation></ref><ref id="hanspub.39534-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">尼菲拉·甫拉提, 菲尔凯提·玉山江, 袁玉娟, 等. 急性冠状动脉综合征患者外周血内皮细胞及红细胞微粒水平分析[J]. 临床心血管病杂志, 2020, 323(5): 68-72.</mixed-citation></ref><ref id="hanspub.39534-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">李彦明, 何瑞利, 钟晓鸣, 等. 急性ST段抬高型心肌梗死患者PCI术后预后评价模型的建立与研究[J]. 重庆医学, 2019, 48(1): 71-75.</mixed-citation></ref><ref id="hanspub.39534-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Claudia, S.A., Livia, P.B., et al. (2020) Lipoprotein (a) Concentration, Genetic Variants, apo(a) Isoform Size, and Cellular Cholesterol Efflux in Patients with Elevated Lp(a) and Coronary Heart Disease Submitted or Not to Lipoprotein Apheresis: An Italian Case-Control Multicenter Study on Lp(a). Journal of Clinical Lipidology, 14, 487-497.  
&lt;br&gt;https://doi.org/10.1016/j.jacl.2020.05.002</mixed-citation></ref><ref id="hanspub.39534-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">温文慧, 匡泽民, 王绿娅. 重新认识脂蛋白(a)促进动脉粥样硬化性心血管疾病的作用[J]. 临床检验杂志, 2018, 36(3): 190-192.</mixed-citation></ref><ref id="hanspub.39534-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Benjamin, E.J., Muntner, P., Alonso, A., et al. (2019) American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics 2019 Update: A Report from the American Heart Association. Circulation, 139, e56-e528.</mixed-citation></ref><ref id="hanspub.39534-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Verbeek, R., Sandhu, M.S., Hovingh, G.K., et al. (2017) Lipoprotein(a) Improves Cardiovascular Risk Prediction Based on Established Risk Algorithms. Journal of the American College of Cardiology, 69, 1513-1515.  
&lt;br&gt;https://doi.org/10.1016/j.jacc.2017.01.017</mixed-citation></ref></ref-list></back></article>